Introduction:
Nitrosamine Testing for Rifabutin is an essential safety and regulatory process used to detect and measure harmful impurities, including N-nitroso-rifabutin, that may develop during manufacturing or storage. This process requires a clear understanding of the spiro-piperidine nitrogen group, which can react under certain conditions, as well as the effect of trace nitrites found in excipients. It also involves reviewing the use of solvents like Dimethylformamide (DMF) and reagents such as N,N-diisopropylethylamine (DIPEA), which are commonly used in production. In addition, environmental and process conditions must be carefully controlled, since even small changes can impact impurity formation. Regulatory bodies expect strong scientific reasoning behind all risk assessments and control plans. Ongoing monitoring across the product lifecycle further supports safety and compliance.
Learn more about our comprehensive analytical services:Nitrosamine Analysis and Testing Services
Share via:
Structural Vulnerability and Nitrosation Mechanisms in the Rifabutin Molecule
The structure of Rifabutin plays a major role in its risk of nitrosamine formation. It contains a complex macrocyclic ansamycin core with an imidazole-spiro-piperidine group, which includes several nitrogen sites that can react. Nitrosamine Testing for Rifabutin focuses especially on the $1’$-nitrogen in the spiro-piperidine ring. This nitrogen is part of a tertiary amine with an isobutyl group, along with nitrogen atoms in the imidazole ring. While tertiary amines are usually less reactive than secondary ones, they can still form nitrosamines through dealkylation under certain conditions. Factors such as temperature, pH, and the presence of nitrosating agents influence these reactions. Understanding these pathways is important for predicting impurity risks and creating effective control strategies.
Rifabutin has a chemical formula of C{46}H{62}N{4}O{11} and a molecular weight of 847.02 \text{ g/mol}, showing its large and complex structure. Even with this complexity, the tertiary amine at the 1′ position can form N-nitroso-rifabutin when exposed to stress conditions or high nitrite levels. Additional risks come from impurities like 3-aminorifamycin S or dealkylated “nor-rifabutin,” which contain more reactive secondary amines. These impurities increase the chance of nitrosamine formation. Monitoring impurity levels during both production and storage is therefore very important, and advanced analytical tools are often needed to detect them accurately.
The macrocyclic structure also affects how the compound behaves during testing. Its lipophilic nature (log P \approx 3.2) requires careful selection of solvents and chromatography conditions to avoid losing trace impurities. In acidic or water-based environments, the tertiary nitrogen may become protonated, but still allows reactions with nitrosating species like NO^+ or N_2O_3. This balance affects how quickly nitrosation occurs. For this reason, Nitrosamine Testing for Rifabutin must consider both chemical behavior and environmental conditions.
Explore specialized testing for complex drug molecules:Nitrosamine Testing for Rifabutin and High-Risk Drug Classes
| Structural Moiety | Functionality | Nitrosation Pathway | Risk Level |
| Spiro-piperidine Ring | Tertiary Amine | Nitrosative dealkylation of the isobutyl group | Moderate |
| Imidazole Fusion | Heterocyclic Nitrogen | Low reactivity due to resonance stabilization | Low |
| Amide Bond | Macrocyclic Amide | Requires extreme hydrolysis to form amines | Very Low |
| Ansa Chain Hydroxyls | Phenolic/Aliphatic | Indirectly influence redox stability | Low |
| Desacetyl Impurities | Secondary Amine | Direct nitrosation of the deacetylated site | High |
Evaluating API Synthesis for Nitrosamine Risks in Nitrosamine Testing for Rifabutin
Nitrosamine Testing for Rifabutin during API production focuses on identifying risks linked to solvents, reagents, and process conditions across a multi-step synthesis. Each stage must be reviewed for possible nitrosamine formation. Special attention is given to steps involving nitrogen-containing compounds, as even very small amounts of contamination can build up over time.
In early stages, solvents like Dimethylformamide (DMF) can break down into dimethylamine (DMA), which is a known precursor for N-nitrosodimethylamine (NDMA). Pyridine, used in several steps, can also form reactive nitroso compounds. These risks highlight the need for strict control of solvent quality and regular testing of raw materials.
A key high-risk stage involves the use of Boc-Piperazine and DIPEA. Piperazine compounds are highly sensitive to nitrosamine formation, especially if deprotection occurs too early. DIPEA can degrade into secondary amines, increasing the overall risk. Other contributors include Imidazole and N-methyl-2-pyrrolidone (NMP), which create a nitrogen-rich environment. Careful process control and high-purity reagents are necessary to reduce these risks.
Nitrogenous Reagents and Solvents in the 20-Step Synthesis
In the multi-step synthesis of Rifabutin, several stages rely on nitrogen-containing solvents and reagents that may contribute to nitrosamine risk if not properly controlled. During Stage 1 and Stage 2, Dimethylformamide (DMF) is widely used as a solvent in early steps, including the formation of the ansamycin core and related functional modifications. DMF requires careful monitoring because it can degrade over time or carry dimethylamine (DMA) as an impurity. DMA is highly reactive with nitrosating agents and can lead to the formation of N-nitrosodimethylamine (NDMA), which is classified as a highly potent carcinogenic impurity. In addition, Pyridine is used in Step 2 and Step 7 as a reagent or catalyst. Although it is a tertiary amine and relatively stable, it may still participate in reactions that form nitrosopyridinium-type species under certain conditions.
A higher level of concern arises in Stage 3, particularly in Step 13, where Boc-Piperazine and N,N-diisopropylethylamine (DIPEA) are used in Dichloromethane (DCM). Piperazine-based compounds are especially sensitive because if the Boc protecting group is removed too early, or if free piperazine remains in the system, there is a strong possibility of forming nitrosamine impurities such as N-nitrosopiperazine (NNP). DIPEA, although a tertiary amine, can degrade into secondary amines, which are more reactive and can easily undergo nitrosation. Moreover, other steps contribute to the overall nitrogen load in the process. For example, Imidazole is used in Step 9, while solvents like N-methyl-2-pyrrolidone (NMP) or DMF are used again in Step 12. Together, these materials maintain a continuous presence of nitrogen-containing species throughout the synthesis, making careful control and monitoring essential.
Discover strategies for process-related impurity control:Nitrosamine Solvent and Catalyst Mitigation Strategies
| Synthesis Step | Reagent/Solvent | Nitrogenous Functionality | Nitrosamine Risk |
| Step 1, 10, 12 | DMF | Amide (precursor to Dimethylamine) | NDMA |
| Step 2, 7 | Pyridine | Tertiary Amine (Aromatic) | N-Nitrosopyridinium |
| Step 9 | Imidazole | Heterocyclic Amine | NDSRI Precursor |
| Step 13 | Boc-Piperazine | Protected Secondary Amine | N-Nitrosopiperazines |
| Step 13 | DIPEA | Tertiary Amine | N-Nitroso-alkylamines |
Nitrosating Agents and Oxidative Pathways in Nitrosamine Testing for Rifabutin
Nitrosating agents, especially nitrite salts, are a major cause of nitrosamine formation. Even if they are not intentionally added, they may appear as impurities in acids used during manufacturing. Oxidative reagents like Pyridinium Chlorochromate (PCC) can also increase the likelihood of nitrosamine formation, particularly under high temperature or oxygen-rich conditions.
Hydrazine-based intermediates present additional concerns, as they can oxidize into nitrosamines. Exposure to oxygen or peroxides can speed up these reactions. Steps involving reagents such as $SeO_2$ and PCC require special attention. Using inert gases like nitrogen and well-designed equipment can help reduce these risks.
Risks from Recovered and Recycled Materials
Recovered solvents such as ethyl acetate, methanol, and acetonitrile may contain leftover amines or nitrites from earlier use. If not properly purified, these impurities can contribute to nitrosamine formation. Cross-contamination is a serious concern, especially in facilities handling multiple products. Strong solvent recovery procedures and regular quality checks are essential.
Reused reagents and catalysts can also degrade over time. For example, tetrabutylammonium fluoride (TBAF) may break down into tertiary amines, which can later form nitrosamines. Evaluating the full recovery and reuse process helps reduce these risks. Using dedicated equipment or validated cleaning steps further improves safety.
Understand the impact of updated regulatory frameworks:Impact of ICH M7(R2) Updates on Nitrosamine Risk Assessment
Evaluating Finished Products in Nitrosamine Testing for Rifabutin
Nitrosamine Testing for Rifabutin in finished products focuses on how the API interacts with excipients. Trace nitrites in excipients can react with the drug during manufacturing or storage. Since Rifabutin is often used in higher doses, even small nitrite levels can become a concern. Supplier quality and consistency are therefore very important.
The tertiary amine in Rifabutin remains a possible reaction site. Over time, degradation products may introduce more reactive secondary amines. Environmental factors like heat and humidity can increase these risks. Stability studies help in understanding and controlling these effects.
Ensure long-term safety with stability testing:Nitrosamine Testing in Stability Studies
Analysis of Nitrite Content in Excipients
Excipients such as microcrystalline cellulose and magnesium stearate may contain low levels of nitrites. Their impact depends on both their concentration and the quantity used in the formulation. Differences between suppliers can also affect risk levels, making testing and specifications essential.
In some formulations, meglumine may add further risk because of its secondary amine structure. It can form N-nitroso-meglumine, which is more strictly regulated. In such cases, multiple nitrosation pathways may occur, requiring a complete and detailed risk assessment.
| Excipient Name | Role in Rifabutin Capsule | Documented Nitrite Range (ppm) | Potential Risk to API |
| Microcrystalline Cellulose | Filler / Binder | 0.04 – 2.4 | High (due to high weight percentage) |
| Magnesium Stearate | Lubricant | 0.1 – 1.5 | Moderate (matrix effects during extraction) |
| Sodium Lauryl Sulfate | Wetting Agent | Variable | Low (impacts microenvironment pH) |
| Gelatin (Capsule Shell) | Container | Variable | Low (potential for cross-linking) |
| Meglumine | Solubilizer (if used) | High | Extreme (is a nitrosatable amine itself) |
Manufacturing Process Impact: Wet Granulation vs Direct Compression
Wet granulation introduces moisture and heat, which can increase nitrosamine formation. Direct compression is often preferred because it avoids these conditions. However, if wet granulation is necessary, strict process controls must be applied.
Mechanical actions like milling can increase contact between the API and excipients, raising the chance of reactions. Forced degradation studies are useful for predicting long-term stability and setting appropriate shelf-life limits.
Regulatory Guidelines and Limits in Nitrosamine Testing for Rifabutin
Regulatory agencies have defined clear limits for nitrosamines in Rifabutin. N-nitroso-rifabutin falls under Potency Category 5, with an acceptable intake limit of 1500 ng/day. Although this indicates a lower level of concern compared to other nitrosamines, compliance is still required.
Ongoing monitoring and updates to regulatory guidance must be followed. Staying current helps manufacturers avoid compliance issues and maintain product availability.
Calculate limits for complex impurities accurately:Nitrosamine CPCA Approach for NDSRIs
Implementation Timelines and Submission Requirements
Global regulations require companies to complete risk assessments and confirmatory testing within set timelines. Deadlines such as August 1, 2025, are critical. Submissions must include detailed findings and control strategies.
If limits are exceeded, a Benefit-Risk Analysis (BRA) may be needed. In some cases, temporary allowances are granted, but corrective actions must be clearly planned. Transparent communication with regulators is essential.
| Agency | Guideline Status (2026) | Primary Requirement | Implementation Deadline |
| USFDA | RAIL Guidance (Aug 2023) | Confirmatory Testing & Mitigation | August 1, 2025 |
| Health Canada | Appendix 1 (Mar 2026) | AI Limit Compliance (1500 ng/day) | August 1, 2025 |
| EU EMA | Article 5(3) Q&A (2026) | Risk Evaluation and Variation Filings | Ongoing |
| WHO PQT | News Update (Oct 2025) | Move from Interim to CPCA Limits | End of 2025 |
Analytical Strategies for Nitrosamine Testing for Rifabutin
Advanced techniques such as LC-MS/MS are commonly used for detecting nitrosamines at very low levels. These methods offer high sensitivity and accuracy. However, the complex structure of Rifabutin makes analysis challenging and requires careful method development.
Matrix effects can affect results, so solutions like diverter valves and specialized columns are used. APCI is sometimes preferred over ESI depending on the compound. Method validation ensures reliable and repeatable results.
Learn about advanced detection technologies:High-Resolution Mass Spectrometry (HRMS) for Nitrosamine Testing
Validation of Ultra-Trace Quantitation Methods
Validation must follow ICH Q2(R1) guidelines, focusing on sensitivity, selectivity, and precision. Detection limits should meet regulatory requirements. Internal standards help improve measurement accuracy, while automation increases consistency.
Proper sample storage is also important to maintain stability. Techniques like low-temperature storage and inert environments are often used. Advanced tools such as Orbitrap HRMS can provide additional confirmation.
Achieve the highest precision in your results:Ultra-Low Limit of Quantitation (LOQ) in Nitrosamine Testing
| Parameter | Regulatory Expectation | Technical Approach |
|---|---|---|
| Sensitivity (LOQ) | ≤ 25% of the AI limit | High-resolution Triple Quadrupole MS (e.g., Agilent 6495D) |
| Selectivity | No interference from API or other impurities | Optimized gradient with diverter valve |
| Linear Range | Typically 10 to 200 ng/mL | Use of isotope-labeled internal standards |
| Stability | Robustness during extraction | Purging with inert gas; storage at low temperature |
| Reproducibility | %RSD ≤ 15% at LOQ | Automated sample preparation |
Mitigation Strategies in Nitrosamine Testing for Rifabutin
Risk reduction strategies include using nitrite scavengers like ascorbic acid and certain amino acids. These compounds react with nitrosating agents before they can form harmful impurities. Choosing excipients with low nitrite levels also helps reduce risk.
Process improvements, such as switching to dry granulation, can lower the chance of nitrosamine formation. Controlling pH and using protective packaging further improves product stability. A complete and proactive approach is the most effective way to manage risk.
Final Insights on Nitrosamine Testing for Rifabutin Compliance
Nitrosamine Testing for Rifabutin plays a key role in ensuring both patient safety and regulatory compliance. A strong understanding of synthesis, formulation, and analytical challenges allows for better risk control. The established intake limit of 1500 ng/day provides a clear safety target.
At ResolveMass Laboratories Inc., the focus is on delivering accurate and dependable testing solutions. Advanced technologies, including high-resolution mass spectrometry, support compliance with global standards. As requirements continue to evolve, proactive and science-based strategies remain essential for maintaining product safety and quality.
Partner with experts for your regulatory submissions:Nitrosamine Risk Assessment for ANDA Submission
FAQs on Nitrosamine Testing for Rifabutin
The most significant impurity is N-nitroso-rifabutin, which is classified as a Nitrosamine Drug Substance-Related Impurity (NDSRI). This molecule forms when the spiro-piperidine tertiary amine center of the drug undergoes nitrosative dealkylation in the presence of nitrosating agents like nitrites. It is structurally unique to Rifabutin and requires dedicated analytical monitoring to ensure levels remain within safe regulatory limits.
According to current USFDA and Health Canada guidelines, the recommended Acceptable Intake (AI) for N-nitroso-rifabutin is 1500 ng/day. It has been categorized as Potency Category 5 based on structural analysis which suggests lower carcinogenic potency compared to simpler nitrosamines. This threshold must be calculated against the maximum daily dose of the medication to establish parts-per-million (ppm) specifications for quality control.
Solvents like Dimethylformamide (DMF) and N-Methyl-2-pyrrolidone (NMP) can degrade into secondary amines (e.g., dimethylamine) during the multi-stage synthesis of Rifabutin. If these amines react with trace nitrites present in reagents or water, they form small-molecule nitrosamines like NDMA. Even if the solvents are not used in the final stage, carry-over and recycling of solvents can introduce these contaminants into the final API.
Excipients like microcrystalline cellulose and magnesium stearate often contain trace levels of inorganic nitrites as unintentional byproducts from their manufacturing processes. In high-dose drugs like Rifabutin (150 mg capsules), the total amount of nitrite introduced by these excipients can be sufficient to nitrosate the API over its shelf-life, particularly when exposed to heat and moisture.
The primary challenge is the “matrix effect” caused by the large, macrocyclic Rifabutin molecule, which can suppress the signal of trace nitrosamines during mass spectrometry. Selective extraction and advanced liquid chromatography techniques, such as using diverter valves to remove the API peak from the ion source, are necessary to achieve the low parts-per-billion (ppb) detection limits required for regulatory compliance.
The synthesis involves several oxidative manipulations, such as the use of Selenium Dioxide ($SeO_2$) and Pyridinium Chlorochromate (PCC). These conditions can facilitate the conversion of residual hydrazines, hydrazides, or hydrazone intermediates into nitrosamines if nitrosating species are present. Controlling atmospheric oxygen and using inert gas purging during these steps is a critical preventative measure.
Recovered solvents can harbor accumulated amine impurities or trace nitrites from previous batches, creating a cross-contamination risk. If the recovery process is not validated to remove these trace components, they can initiate nitrosamine formation in subsequent synthesis runs. Strict monitoring of recycled materials is a mandatory part of a robust nitrosamine risk assessment.
Unlike Rifampicin and Rifapentine, which had higher “interim limits” (e.g., 5 ppm or 20 ppm) to avoid shortages, Rifabutin is generally expected to meet the CPCA-derived AI of 1500 ng/day. However, if a manufacturer identifies levels slightly above this threshold, they may apply for a scientific justification for continued distribution based on a benefit-risk analysis for this essential antibiotic.
Reference:
- Gao, Y., Wang, J., & Zhang, L. (2022). Nitrosamine impurities in pharmaceuticals: Chemistry, formation, and control strategies. Frontiers in Chemistry, 10, 9146227. https://doi.org/10.3389/fchem.2022.9146227
- U.S. Food and Drug Administration. (2023). CDER nitrosamine impurity acceptable intake limits. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits
- Health Canada. (2023). Nitrosamine impurities in medications. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities.html
- Giovagnoli, S., Blasi, P., Ricci, M., & Rossi, C. (2004). Rifapentine compositions and process for their preparation (WO2004005298A1). Google Patents. https://patents.google.com/patent/WO2004005298A1/en
- U.S. Food and Drug Administration. (2024). Information about nitrosamine impurities in medications. https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications
- Health Canada. (2023). Nitrosamine impurities: Established acceptable intake limits. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/established-acceptable-intake-limits.html
- International Agency for Research on Cancer. (2010). Some N-nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 94. https://pmc.ncbi.nlm.nih.gov/articles/PMC2866172/
Get In Touch With Us
About The Author
